|
|
|
| home > contact us |
|
|
 CONTACT US |
| |
|
|
|
|
Address
|
Samedan Ltd
Suite E, 11 Bell Yard Mews
175 Bermondsey Street
London
SE1 3TN
|
|
|
|
|
Email
|
info@samedanltd.com
|
|
|
|
|
Telephone Number
|
+44 (0)20 7724 3456
|
|
|
|
|
Fax Number
|
+44 (0)20 7403 7747
|
|
|
|
|
Subscriptions and Data Management
Beeline Data Services Ltd
Tel: 01342 312593
Fax: 01342 770131
Email: samedan@beelinedata.co.uk
www.beelinedata.co.uk |
|
|
|
|
|
Rights / Permissions
Welcome to Samedan’s permissions enquiry page.
For all permissions requests to reuse content from Samedan Ltd are now being processed through PLSclear.
Search for the article you wish to use by title, author name, article title, author name, Article No or Company; complete
the
following form with as much information as possible;
and submit. We will respond as quickly as possible (info@samedanltd.com) |
|
|
|
|
|
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
 |
News and Press Releases |
 |
Avacta announces license agreement with POINT Biopharma Inc.
Cambridge and Wetherby, UK, 07 January 2021: Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc. (“POINT”), to provide access to Avacta’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.
More info >> |
|
|
